Literature DB >> 31980062

Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome?

Julia J Scarisbrick1.   

Abstract

Early-stage mycosis fungoides (MF) has been associated with long survival. A recent meta-analysis including 6,279 patients with MF and Sezary syndrome found that about 10-20% of stage IB patients don't survive 5 years, whereas patients with advanced-stage MF and Sezary syndrome have a 5-year survival chance of about 20-60%. Identifying prognostic markers to better identify those at risk of limited survival may allow improved management choices and this, coupled with newer treatments, could improve survival.
Copyright © 2019 The Author. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 31980062     DOI: 10.1016/j.jid.2019.08.440

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

Review 1.  Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.

Authors:  Kamila Polgárová; Pavel Otáhal; Cyril Šálek; Robert Pytlík
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

2.  Proteomic identification of new diagnostic biomarkers of early-stage cutaneous mycosis fungoides.

Authors:  Ling Leng; Zhaorui Liu; Jie Ma; Shiyu Zhang; Yukun Wang; Luye Lv; Yunping Zhu; Dunqin Gao; Yujie Wang; Juncheng Wang; Yuehua Liu; Jie Liu
Journal:  Cancer Commun (Lond)       Date:  2022-01-20

3.  Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.

Authors:  E Papadavid; J Scarisbrick; P Ortiz Romero; P Guaglino; M Vermeer; R Knobler; R Stadler; M Bagot
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-07       Impact factor: 9.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.